229 related articles for article (PubMed ID: 22320315)
41. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
42. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
[TBL] [Abstract][Full Text] [Related]
43. Dysregulated expression of dicer and drosha in breast cancer.
Yan M; Huang HY; Wang T; Wan Y; Cui SD; Liu ZZ; Fan QX
Pathol Oncol Res; 2012 Apr; 18(2):343-8. PubMed ID: 21898071
[TBL] [Abstract][Full Text] [Related]
44. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia.
Yang YQ; Tian T; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Wang L; Fan L; Li JY; Xu W
BMC Cancer; 2018 Oct; 18(1):1009. PubMed ID: 30348117
[TBL] [Abstract][Full Text] [Related]
45. TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia.
Szymańska A; Bojarska-Junak A; Drobiecki A; Tomczak W; Roliński J; Hus M; Hus I
Arch Immunol Ther Exp (Warsz); 2019 Feb; 67(1):55-65. PubMed ID: 30196472
[TBL] [Abstract][Full Text] [Related]
46. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
47. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer.
Erler P; Keutgen XM; Crowley MJ; Zetoune T; Kundel A; Kleiman D; Beninato T; Scognamiglio T; Elemento O; Zarnegar R; Fahey TJ
Surgery; 2014 Dec; 156(6):1342-50; discussion 1350. PubMed ID: 25456905
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
[TBL] [Abstract][Full Text] [Related]
49. Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.
Prodromaki E; Korpetinou A; Giannopoulou E; Vlotinou E; Chatziathanasiadou Μ; Papachristou NI; Scopa CD; Papadaki H; Kalofonos HP; Papachristou DJ
Cell Oncol (Dordr); 2015 Aug; 38(4):307-17. PubMed ID: 26227789
[TBL] [Abstract][Full Text] [Related]
50. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
[TBL] [Abstract][Full Text] [Related]
51. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.
Dickinson JD; Gilmore J; Iqbal J; Sanger W; Lynch JC; Chan J; Bierman PJ; Joshi SS
Leuk Lymphoma; 2006 Feb; 47(2):231-44. PubMed ID: 16321852
[TBL] [Abstract][Full Text] [Related]
52. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
Kröber A; Seiler T; Benner A; Bullinger L; Brückle E; Lichter P; Döhner H; Stilgenbauer S
Blood; 2002 Aug; 100(4):1410-6. PubMed ID: 12149225
[TBL] [Abstract][Full Text] [Related]
53. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
[TBL] [Abstract][Full Text] [Related]
54. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
Weinberg JB; Volkheimer AD; Chen Y; Beasley BE; Jiang N; Lanasa MC; Friedman D; Vaccaro G; Rehder CW; Decastro CM; Rizzieri DA; Diehl LF; Gockerman JP; Moore JO; Goodman BK; Levesque MC
Am J Hematol; 2007 Dec; 82(12):1063-70. PubMed ID: 17654680
[TBL] [Abstract][Full Text] [Related]
55. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.
Gonzalez D; Else M; Wren D; Usai M; Buhl AM; Parker A; Oscier D; Morgan G; Catovsky D
Haematologica; 2013 Feb; 98(2):274-8. PubMed ID: 22899580
[TBL] [Abstract][Full Text] [Related]
56. miR-34a and miR-29b as indicators for prognosis of treatment-free survival of chronic lymphocytic leukemia patients in Chinese Uygur and Han populations.
Li Y; Mao M; Liu H; Wang X; Kou Z; Nie Y; Wang Y; Wang Z; Huang Q; Lang T; Gu Z; An L; Zhang X; Fu L
Mol Cell Probes; 2019 Oct; 47():101436. PubMed ID: 31425738
[TBL] [Abstract][Full Text] [Related]
57. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
58. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
[TBL] [Abstract][Full Text] [Related]
59. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.
Zhang L; Murray F; Rassenti LZ; Pu M; Kelly C; Kanter JR; Greaves A; Messer K; Kipps TJ; Insel PA
Int J Cancer; 2011 Sep; 129(5):1162-9. PubMed ID: 21120911
[TBL] [Abstract][Full Text] [Related]
60. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
